Orodispersible tablets (ODTs), also known as fast melt, quick melts, fast disintegrating have the unique property of disintegrating in the mouth in seconds without chewing and the need of water. Oral bioavailability of Atorvastatin Calcium is low (14%) and shows extensive intestinal clearance and first-pass metabolism, which is the main cause for the low systemic availability. In the present work, orodispersible tablets of Atorvastatin calcium were prepared by direct compression method using Hibiscus rosa sinesis mucilage as natural superdisintegrant with a view to enhance patient compliance and to avoid hepatic first pass metabolism and to improve its bioavailability. The prepared batches of tablets were evaluated for hardness, friability, drug content uniformity, wetting time, water-absorption ratio and in-vitro dispersion time. Short-term stability studies on the promising formulation indicated that there are no significant changes in drug content and in vitro dispersion time.
INTRODUCTION
Oral delivery is current standard in the pharmaceutical industry wherever it is regarded as the safest, most suitable and most economical method of drug delivery. The oral cavity is an attractive site for the administration of drugs because of ease of administration.
Oro-dispersible drug delivery system are Novel Drug Delivery techniques that make the tablets disintegrate in the mouth without chewing and water, and immediate release and enhanced bioavailability, with better patient compliance.
Recently, the European Pharmacopeia adopted the term orodispersible tablet for a tablet that disperses or disintegrates within a minute or second in the mouth before swallowing.
United States Food and Drug Administration (FDA) defined Oro-dispersible tablet as "a solid dosage form containing medicinal substances or active ingredient which disintegrate or dissolve rapidly within seconds when placed upon the tongue.
Oro-dispersible tablets have a quick dissolution and rapid absorption which provide rapid onset of action. Moreover, drug candidates that undergo pregastric absorption when formulated as ODTs may oral bioavailability of drug is enhanced by avoiding the hepatic first pass metabolism. It provides good stability, accurate dosing, easy of manufacturing. Oro-dispersible tablets are made by a direct compression method using super Disintegrate as an important component. 
MATERIAL AND METHODS

Materials
Methods
Drug Characterization
Melting point determination
Capillary tube was taken and one end was sealed by heating. Capillary tube was filled with drug powder upto 2-3mm high. The capillary tube was putted inside melting point apparatus and temperature was increased slowly. The temperature was noted when the drug gets starts melting and again noted when drugs completely melted.
UV Spectroscopy
50mg of drug was weighed and was dissolved in 50ml of methanol (1mg/ml). 10ml of this solution was withdrawn and volume was made up to 100ml. Appropriate dilutions were made with methanol to give concentration of 10 μg/ml, scanned in UV range from 200-400nm, which could be utilized for analysis and spectrum was recorded.
Calibration curve
Accurately weighed 50mg of Atorvastatin Calcium was transferred into a 500ml volumetric flask & dissolved in phosphate buffer 6.8. Then sonicated for 15 minute and the volume was made up with phosphate buffer pH 6.8 to obtain a 100µg/ml stock solution of Atorvastatin Calcium. 
Solubility studies
An excess amount of prepared Atorvastatin-β-cyclodextrin inclusion complex at different concentration (1:3, 1:4, 1:5) were separately dissolved in 5ml phosphate buffer pH 6.8 in vials and sealed properly and stirred continuously. The process was repeated until saturation solubility of inclusion complex. The solution was kept for 24 hours at room temperature. Then solution was filtered. The adequately diluted with phosphate buffer pH 6.8. Then solution was analyzed by using UV-visible spectrophotometer at 245.40nm. 
Solubility enhancement by Inclusion Complex
An excess amount of prepared Atorvastatin-β-cyclodextrin inclusion complex at different concentration (1:3, 1:4, 1:5) were separately dissolved in 5ml phosphate buffer pH 6.8 in vials and sealed properly and stirred continuously. The process was repeated until saturation solubility of inclusion complex. The solution was kept for 24 hours at room temperature then solution was filtered. The solubility was determined by using UV-Spectroscopy. 
Evaluation of Tablet

Weight variation
Randomly, twenty tablets were selected after compression and the mean weight was determined. None of the tablets deviated from the average weight by more than ±7.5% (USPXX).
 Thickness
Thickness of tablet was determined by using vernier calliper (Mitutoya, Model CD-6 CS, Japan).
 Hardness
The crushing strength of the tablets was measured using a Monsanto hardness tester (Sheetal Scientific Industries, Mumbai, India). Three tablets from each formulation batch were tested randomly and the average reading noted.
 Friability
Twenty tablets were weighed and placed in a Roche friabilator (Electrolab, India). Twenty reweighed tablets were rotated at 25 rpm for 4 min. The tablets were then dedusted and reweighed and the percentage of weight loss was calculated. The percentage friability of the tablets were measured as per the following formula,
Percentage friability = Initial weight-Final weight x 100
Initial weight 
Wetting time
A piece of circular tissue paper (8cm) folded twice was placed in a Petri dish (Internal Diameter = 9cm) containing 10 ml of buffer solution simulating saliva pH 6.8. A tablet was placed on the paper and the time taken for complete wetting was noted. Three tablets from each formulation were randomly selected and the average wetting time was noted. The results are tabulated in Table 6 .

Water absorption ratio
A piece of tissue paper folded twice was placed in a small petri dish containing 6 ml of water. A tablet was put on the tissue paper and allowed to completely wet. The wetted tablet was the reweighed. Water absorption ratio, R was determined using following equation-
R = 100 × Wa-Wb/Wa
Where, Wa = Weight of tablet after water absorption Wb = Weight of wetted tablet before water absorption 
Disintegration Time
One tablet was introduced into each tube and disc was added to each tube. The assembly was introduced in the beaker containing purified water. The apparatus operated until the tablet completely disintegrate. The time was noted down until the tablets completely disintegrate. The assembly was removed from water.
 Dissolution Study
In vitro release of Atorvastatin calcium from tablets was monitored by using 900 ml of simulated intestinal fluid, SIF (USP phosphate buffer solution, pH 6.8) at 37±0.5 0 C and 50 rpm using programmable dissolution tester [Paddle type, model TDT-08L, Electrolab, (USP), India]. 5 ml Aliquots were withdrawn at one minute time intervals and were replenished immediately with the same volume of fresh buffer medium. Aliquots, following suitable dilutions, were assayed spectrophotometrically (UV-1700, Shimadzu, Japan) at 245.5 nm.
RESULT AND DISCUSSION
Mouth dissolving drug delivery is rapidly gaining acceptance as an important drug delivery technology. In such drug delivery, different dosage forms disintegrate rapidly in the patient's mouth within a minute and can be gulped easily without need of water. This rapid disintegration can be achieved by use of high levels of disintegrate and/or effervescent agents along with water soluble diluents. Hence, it offers increased patient compliance and convenience. orodispersible tablet of Atorvastatin calcium was formulated. Total nine batches were prepared for orodispersible formulation. All the formulations were subjected to evaluation, Tablet weight varied from 110 to 120 mg, and thickness 3 to 4.1 mm. All the tablets exhibited friability values between 0.5 to 0.8, all tablets disintegrated in less than 1 minute. The drug released at the time interval of 30 minutes upto 97.5% of batch F9. 
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